You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Unresectable carcinoma

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Unresectable Hepatocellular Carcinoma Trial in Nanjing (Yttrium-90 carbon microspheres SIRT)

Recruiting
  • Unresectable Hepatocellular Carcinoma
  • Yttrium-90 carbon microspheres SIRT
  • Nanjing, China
    Gao-Jun Teng
Jul 20, 2023

Hepatocellular Carcinoma Trial in Shanghai (M-TACE)

Enrolling by invitation
  • Hepatocellular Carcinoma
  • M-TACE
  • Shanghai, Shanghai, China
    Department of Interventional Radiology, Zhongshan Hospital, Fuda
May 24, 2023

Hepatocellular Carcinoma Non-resectable Trial in Taoyuan City (Atezolizumab, Bevacizumab, Proton radiotherapy)

Recruiting
  • Hepatocellular Carcinoma Non-resectable
  • Taoyuan City, Taiwan
    Chang Gung Memorial Hospital at Linkou
Nov 17, 2023

Hepatocellular Carcinoma Trial (Atezolizumab, Bevacizumab)

Not yet recruiting
  • Hepatocellular Carcinoma
  • (no location specified)
Oct 18, 2023

Adebrelimab, Hepatocellular Carcinoma, Transformation Trial in Xiamen (TACE with adebrelimab and bevacizumab)

Not yet recruiting
  • Adebrelimab
  • +4 more
  • TACE with adebrelimab and bevacizumab
  • Xiamen, Fujian, China
    The First Affiliated Hospital of Xiamen University
Jul 25, 2023

Unresectable Hepatocellular Carcinoma, Oligometastatic Disease Trial in Beijing (SBRT plus tislelizumab and regorafenib)

Recruiting
  • Unresectable Hepatocellular Carcinoma
  • Oligometastatic Disease
  • SBRT plus tislelizumab and regorafenib
  • Beijing, Beijing, China
    Peking University Cancer Hospital
Jun 15, 2023

Hepatocellular Carcinoma Trial in Guangzhou (Lenvatinib, sintilimab plus SIRT)

Not yet recruiting
  • Hepatocellular Carcinoma
  • Lenvatinib, sintilimab plus SIRT
  • Guangzhou, Guangdong, China
    The Second Affiliated Hospital of Guangzhou Medical University
Aug 8, 2023

Hepatocellular Carcinoma Trial in Shanghai (Cadonilimab+TACE)

Active, not recruiting
  • Hepatocellular Carcinoma
  • Shanghai, Shanghai, China
    Eastern hepatobilliary surgery hospital
Jun 21, 2023

Hepatocellular Carcinoma (HCC) Trial (Durvalumab, Bevacizumab, Transarterial Radioembolization (TARE))

Not yet recruiting
  • Hepatocellular Carcinoma (HCC)
  • (no location specified)
Sep 11, 2023

Unresectable Pancreatic Cancer, Unresectable Bile Duct Carcinoma, Unresectable Biliary Tract Carcinoma Trial (Tripegfilgrastim)

Not yet recruiting
  • Unresectable Pancreatic Cancer
  • +2 more
  • (no location specified)
Nov 13, 2023

Patterns of Transcatheter Arterial Chemoembolization Combined

Not yet recruiting
  • HCC
  • (no location specified)
Aug 29, 2023

Unrescetable Hepatocellular Carcinoma Trial in Tianjin (HAIC+Durvalumab+Tremelimumab+Bevacizumab)

Not yet recruiting
  • Unrescetable Hepatocellular Carcinoma
  • Tianjin, Tianjin, China
    Tianjin Cancer Hospital Airport Hospital
May 16, 2023

Unresectable Hepatocellular Carcinoma Trial in Changsha (Donafenib Tosilate Tablets, Toripalimab Injection)

Recruiting
  • Unresectable Hepatocellular Carcinoma
  • Donafenib Tosilate Tablets
  • Toripalimab Injection
  • Changsha, Hunan, China
    Hunan Cancer Hospital
Nov 28, 2022

Hepatocellular Carcinoma Trial in Guangzhou (TACE-HACI, plus atezolizumab-bevacizumab)

Recruiting
  • Hepatocellular Carcinoma
  • TACE-HACI, plus atezolizumab-bevacizumab
  • Guangzhou, Guangdong, China
    Sun Yat-sen University Cancer Center
Feb 20, 2023

Unrescetable Hepatocellular Carcinoma Trial in Tianjin (HAIC+Cadonilimab+Bevacizumab)

Not yet recruiting
  • Unrescetable Hepatocellular Carcinoma
  • Tianjin, Tianjin, China
    Tianjin Cancer Hospital Airport Hospital
Apr 7, 2023

Locally Advanced Unresectable Esophageal Squamous Carcinoma Trial in Jinan, Tianjin (Docetaxel for Injection (Albumin-bound),

Not yet recruiting
  • Locally Advanced Unresectable Esophageal Squamous Carcinoma
  • Docetaxel for Injection (Albumin-bound)
  • +4 more
  • Jinan, Shandong, China
  • +1 more
Nov 16, 2023

Esophageal Squamous Cell Carcinoma Trial in Shanghai (Tirelizumab, Nab paclitaxel, Carboplatin)

Recruiting
  • Esophageal Squamous Cell Carcinoma
  • Shanghai, Shanghai, China
    Ruijin hospital, Shanghai jiaotong university school of medicine
Nov 6, 2023

Ampullary Carcinoma Trial (Surufatinib+Toripalimab+AG)

Not yet recruiting
  • Ampullary Carcinoma
  • (no location specified)
Sep 29, 2023

Hepatocellular Carcinoma Non-resectable, Portal Vein Tumor Thrombus, Immune Checkpoint Inhibitors Trial in Nanning (Cadonilimab,

Recruiting
  • Hepatocellular Carcinoma Non-resectable
  • +2 more
  • Nanning, Guangxi, China
    First Affiliated Hospital of Guangxi Medical University
Sep 13, 2023

Hepatocellular Carcinoma Trial in Taoyuan (ADI-PEG20)

Recruiting
  • Hepatocellular Carcinoma
  • Taoyuan, Taiwan
    Chang Gung Memorial Hospital, Linkou branch
Sep 6, 2023

Tislelizumab, Lenvatinib, TACE Trial in Nanning (Tislelizumab and Lenvatinib)

Active, not recruiting
  • Tislelizumab
  • +3 more
  • Tislelizumab and Lenvatinib
  • Nanning, Guangxi, China
    The Affiliated Cancer Hospital of Guangxi Medical University
Jan 25, 2023

Hepatocellular Carcinoma Trial (Lenvatinib at a dose of 8 mg or 12 mg based on body weight + tislelizumab for one 21-day cycle)

Not yet recruiting
  • Hepatocellular Carcinoma
  • Lenvatinib at a dose of 8 mg or 12 mg based on body weight + tislelizumab for one 21-day cycle
  • (no location specified)
Jun 12, 2023

Unresectable Hepatocellular Carcinoma (HCC) Trial in Milano, Rozzano, Barcelona (NMS-01940153E)

Recruiting
  • Unresectable Hepatocellular Carcinoma (HCC)
  • Milano, Italy
  • +2 more
Dec 2, 2022

Hepatocellular Carcinoma Trial in Seoul (Lenvatinib)

Recruiting
  • Hepatocellular Carcinoma
  • Seoul, Korea, Republic of
    Asan Medical Center
Nov 14, 2023

Squamous Cell Carcinoma Trial (MK-3475A)

Not yet recruiting
  • Squamous Cell Carcinoma
  • MK-3475A
  • (no location specified)
Sep 11, 2023